With coronavirus beginning its worldwide spread in February, France’s Sanofi (SNY) revealed plans to spin off its active pharmaceutical ingredients (API) business into a standalone company. For the sake of layman like us, APIs are the ‘magic’ molecules that make drugs work and according to Sanofi, the vast majority of APIs are currently manufactured in Asia (ex China… Read More »
From its spinoff from Biogen(BIIB) in February 2017 to the closing of its acquisition by Sanofi(SNY) in March 2018, Bioverativ’s tenure as a public company was short but profitable. From an initial price of $44.98 to the sale price of $105 in cash, Bioverativ stock, trading under the symbol BIVV, increased 133%. Not bad for 13 months. We… Read More »
It was just one year ago when Biogen(BIIB) spun off hemophilia and blood disorder specialist Bioverativ(BIVV). With the stock trading in the 40s post-spin, we highlighted some disparate analyst opinions of the spin. The most bullish, Gabelli & Company, has a price target of $58 for Bioverativ stock. This past Friday, Bioverativ stock closed at $64.11, above Gabelli’s… Read More »